Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145

Benzinga Newsdesk www.benzinga.com Neutral 71.0%

Neg 0% Neu 71% Pos 0%

Jefferies analyst Andrew Tsai initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Buy rating and announces Price Target of $145.